Shubh Goel: Recently, I spoke to a Pharmaceutical Executive following data presented at ASCO GI from our EMERALD-1 and MATTERHORN Phase III trials

Shubh Goel, VP and US Franchise Head, Immuno-Oncology and GI Tumors at AstraZeneca, shared a post on LinkedIn:

“This post is intended for a US audience. Recently, I spoke to a Pharmaceutical Executive following data presented at ASCO GI from our EMERALD-1 and MATTERHORN Phase III trials, in liver cancer and gastric cancer, respectively.

At AstraZeneca, we believe if we can intervene earlier, we have a better chance of improving long-term outcomes for patients, so it was great to share more about our extensive clinical development program to treat GI cancers earlier. Thanks for chatting with me, Donald Tracy!”

Read further.

Source: Shubh Goel/LinkedIn